2-(3,4-dichlorophenyl)-3,4-dihydroquinazoline-4-one | 285988-42-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(3,4-dichlorophenyl)-3,4-dihydroquinazoline-4-one
• 英文别名: 2-(3,4-dichlorophenyl)quinazolin-4(3H)-one；2-(3,4-Dichlorophenyl)quinazolin-4(1H)-one；2-(3,4-dichlorophenyl)-3H-quinazolin-4-one
• CAS: 285988-42-3
• 化学式: C₁₄H₈Cl₂N₂O
• 分子量: 291.136
• InChiKey: WGZNQYHSWMOAOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  456.5±55.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3,4-二氯碘苯 、 2-isocyanobenzamide 在 iron(II,III) oxide 、 caesium carbonate 、 钯 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以86%的产率得到2-(3,4-dichlorophenyl)-3,4-dihydroquinazoline-4-one
  参考文献：
  名称：

  Pd / Fe 3 O 4负载在氮掺杂的还原氧化石墨烯上，用于室温下异氰酸酯的插入反应† ‡

  摘要：

  开发了一种多功能的Pd / Fe 3 O 4负载在N掺杂的还原氧化石墨烯（N-rGO）催化剂上，以在极温和的条件下通过异氰酸酯插入级联反应进行喹唑啉酮和菲啶的合成。负载的Pd / Fe 3 O 4纳米颗粒可以很容易地从反应混合物中回收并重复使用数次，而不会降低催化活性。

  DOI：

  10.1039/c5cy01973g

文献信息

• Synthesis of 2-Arylquinazolin-4(3<i>H</i>)-one Derivatives Catalyzed by Iodine in [bmim⁺][ ]
  作者：Xiang-Shan Wang、Ke Yang、Mei-Mei Zhang、Chang-Sheng Yao

  DOI：10.1080/00397910903318609

  日期：2010.8.5

  Controlling selectivity of the reactions of aromatic aldehydes and 2-aminobenzamide in ionic liquid catalyzed by iodine at either room temperature or at 80 °C under nitrogen resulted in the synthesis of (E)-Schiff bases, 2,3-dihydro-2-arylquinazolin-4(1H)-one and 2-arylquinazolin-4(3H)-one derivatives, in excellent yields.

  在室温或 80 °C 氮气氛下，控制芳香醛和 2-氨基苯甲酰胺在碘催化的离子液体中反应的选择性导致合成（E）-席夫碱、2,3-二氢-2-芳基喹唑啉-4(1H)-one 和 2-芳基喹唑啉-4(3H)-one 衍生物，产率极好。
• Pyrazole compounds useful as protein kinase inhibitors
  申请人：——

  公开号：US20040224944A1

  公开（公告）日：2004-11-11

  This invention describes novel pyrazole compounds of formula IV: 1 wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R 2 , R 2′ , T, and R 3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  本发明描述了公式IV：1的新型吡唑化合物，其中环D是从芳基，杂芳基，杂环基或碳环基中选择的5-7成员单环或8-10成员双环。 Rx和Ry独立选择自T-R3，或者与它们之间的原子结合形成融合的，不饱和的或部分不饱和的5-8成员环，其中有1-3个环杂原子，所述的杂原子选择自氧，硫或氮。 R2，R2'，T和R3如说明书所述。这些化合物可用作蛋白激酶抑制剂，特别是作为aurora-2和GSK-3的抑制剂，用于治疗癌症，糖尿病和阿尔茨海默病等疾病。
• Triazole compounds useful as protein kinase inhibitors
  申请人：——

  公开号：US20040097501A1

  公开（公告）日：2004-05-20

  This invention describes novel triazole compounds of formula IX: 1 wherein Z 1 is nitrogen or CR 9 and Z 2 is nitrogen or CH, provided that at least one of Z 1 and Z 2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R 1 ; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or R x and R y are taken together with their intervening atoms to form a fused ring; R 1 , R 3 , and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.

  本发明描述了式IX的新型三唑类化合物：其中Z1是氮或CR9，Z2是氮或CH，但至少其中一个为氮；G为环C或环D；环C选自苯基、吡啶基、嘧啶基、吡嗪基、吡咯基或1,2,4-三嗪基环，其中所述环C具有一个或两个独立选择自—R1的邻位取代基；环D为选自芳基、杂芳基、杂环基或碳环基的5-7成员单环或8-10成员双环；Rx和Ry独立选择自T-R3，或Rx和Ry连同它们之间的原子形成融合环；R1、R3和T如说明书所述。该化合物可用作蛋白激酶抑制剂，特别是GSK-3和Aurora的抑制剂，用于治疗糖尿病、癌症和阿尔茨海默病等疾病。
• TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Bebbington David

  公开号：US20120071657A1

  公开（公告）日：2012-03-22

  This invention describes novel triazole compounds of formula IX: wherein Z 1 is nitrogen or CR 9 and Z 2 is nitrogen or CH, provided that at least one of Z 1 and Z 2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R 1 ; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or R x and R y are taken together with their intervening atoms to form a fused ring; R 1 , R 3 , and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.

  该发明描述了式IX的新型三唑类化合物：其中Z1是氮或CR9，Z2是氮或CH，但至少其中一个为氮；G是环C或环D；环C选自苯基、吡啶基、嘧啶基、吡嗪基、吡咯基或1,2,4-三嗪基环，其中所述的环C具有一个或两个独立选择自-R1的邻位取代基；环D是选自芳基、杂芳基、杂环基或碳环基的5-7成员单环或8-10成员双环环；Rx和Ry独立选择自T-R3，或Rx和Ry与它们之间的原子结合形成螺合环；R1、R3和T如说明书所述。该化合物可用作蛋白激酶抑制剂，特别是GSK-3和Aurora的抑制剂，用于治疗糖尿病、癌症和阿尔茨海默病等疾病。
• PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Bebbington David

  公开号：US20100256170A1

  公开（公告）日：2010-10-07

  This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R 2 , R 2′ , T, and R 3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  本发明描述了式IV的新型吡唑化合物：其中环D为5-7成员单环或8-10成员双环，选自芳基，杂芳基，杂环基或碳环基；Rx和Ry分别选自T-R3，或与其之间的原子结合形成融合的、不饱和或部分不饱和的5-8成员环，其中有1-3个选自氧、硫或氮的环杂原子；R2、R2'、T和R3如说明书所述。这些化合物可用作蛋白激酶抑制剂，特别是aurora-2和GSK-3的抑制剂，用于治疗癌症、糖尿病和阿尔茨海默病等疾病。